Authors

Louise J Maple-Brown

MBBS, FRACP, PhD, Head, Department of Endocrinology, Royal Darwin Hospital, NT; Head, Diabetes across the Lifecourse: Northern Australia Partnership, Menzies School of Health Research, Charles Darwin University, NT


Current evidence and practical guidance for the use of sodium–glucose co-transporter-2 inhibitors in type 2 diabetes

Sodium–glucose co-transporter-2 inhibitors are becoming a cornerstone of therapy for type 2 diabetes, kidney disease and heart failure.